Genmab A/S

Genmab A/S

515.53
USD
+6.03
(+1.18%)
11.44EPS
30.11P/E
21.83BMarket Cap
Feb 24Next Earn
Genmab A/S
OTC:GNMSF
(OTC Markets)

Recent

price

515.53

P/E

ratio

30.11

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
0.42
0.24
0.33
0.44
0.4
0.41
0.61
1.01
7.56
1.92
4.21
2.99
31.74
36.59
48.62
59.85
69.48
Revenue per Share
-0.23
-0.4
-0.33
0.08
0.14
0.28
0.4
0.47
3.68
0.77
1.98
1.05
11.93
9.66
17.65
15.49
11.79
Basic EPS, GAAP
0.18
-0.3
0.04
-0.09
0.03
0.06
0.1
0.64
1.34
0.43
2.55
0.7
7.87
15.57
16.86
18.2
13.63
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.77
0.33
0.24
0.43
0.95
1.25
1.6
2.67
20.02
4.87
7.93
7.87
60.07
71.74
80.85
94.92
102.99
Book Value per Share
0.77
0.33
0.24
0.43
0.92
1.18
1.54
2.62
18.85
4.71
7.79
7.78
59.75
71.51
48.06
-58.95
-46.58
Tangible Book Value per Share
45
45
46
51
56
59
60
61
61
63
65
66
66
65
64
62
62
Basic Weighted Avg Shares
19
11
15
23
23
24
36
61
463
121
274
196
2,088
2,390
3,121
3,720
4,296
Sales/Revenue/Turnover
-27.61
-71.07
-24.08
10.44
31.18
64.46
57.97
56.83
45.62
49.16
62.44
35.08
43.21
32.3
32.52
33.6
30.63
Operating Margin (%)
1
- -
- -
- -
- -
1
1
2
13
3
7
6
52
43
60
71
103
Depreciation Expense
-10
-18
-15
4
8
16
24
29
225
49
129
69
785
631
1,133
963
729
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
8.68
24.24
19.41
24.53
21.5
22.77
14.56
20.02
6.3
Effective Tax Rate (%)
-55.23
-169.94
-100.51
16.93
35.43
67.39
65.36
46.68
48.66
40.37
47.06
35.13
37.59
26.4
36.3
25.89
16.97
Profit Margin (%)
35
16
15
27
56
69
90
149
1,071
293
476
493
3,799
4,544
3,156
1,458
1,889
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
8
8
75
101
131
5,135
4,850
LT Debt
35
15
12
22
54
74
97
163
1,228
316
519
517
3,927
4,687
5,137
5,847
6,333
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
27.38
5.73
32.51
9.84
31.2
13.52
16.08
10.12
11.15
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
32.43
6.31
30.52
13.1
34.77
14.49
22.78
12.22
12.42
Return on Capital (%)
-24.91
-73.48
-113.88
22.21
20.92
25.39
27.8
22.1
32.43
6.31
30.93
13.29
35.32
14.65
23.07
17.53
12.07
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
293
312
348
LT Borrowings
4,933
4,841
4,674
LT Finance Leases
125
120
176
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
61
61
61
Market Capitalization
16,269
16,895
21,829

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,573
2,801
3,188
Cash, Cash Equivalents & STI
1,521
1,503
1,860
Accounts Receivable, Net
968
1,212
1,241
Inventories
21
18
30
Total Current Liabilities
1,178
1,140
1,299
Payables & Accruals
861
807
932
ST Debt
293
312
348
Deferred Revenue
24
21
19

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
144.38%
140.4%
13.82%
Free Cash Flow
222.99%
211.91%
4.53%
Net Income, GAAP
187.71%
207.56%
-15%
Sales/Revenue/Turnover
182.76%
200.15%
19.19%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
87
112
122
744
3,121
2025
104
925
1,022
1,058
3,720
2026
896
1,155
1,187
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.43
0.45
0.44
7.8
17.65
2025
0.44
5.44
6.51
0.5
15.49
2026
0.84
4.94
5.58
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Genmab A/S is a Danish biotechnology company that creates, develops and commercializes differentiated antibody therapeutics focused on oncology and other serious diseases; its core offerings include proprietary technologies such as DuoBody, HexaBody, DuoHexaBody and HexElect for bispecific and multispecific antibodies, alongside marketed products like EPKINLY (epcoritamab, a CD3xCD20 bispecific for relapsed/refractory diffuse large B-cell lymphoma, partnered 50:50 with AbbVie), Tivdak (tisotumab vedotin, a tissue factor-directed antibody-drug conjugate for recurrent or metastatic cervical cancer, partnered 50:50 with Seagen), and royalty-generating partnered medicines including DARZALEX/DARZALEX Faspro (daratumumab for multiple myeloma and AL amyloidosis, Janssen), Kesimpta (ofatumumab for relapsing remitting multiple sclerosis, Novartis), Rybrevant (amivantamab for non-small cell lung cancer, Janssen), Talvey (talquetamab for relapsed/refractory multiple myeloma, Janssen), Tecvayli (teclistamab for relapsed/refractory multiple myeloma, Janssen) and Tepezza (teprotumumab for thyroid eye disease, Horizon); the company maintains a robust pipeline encompassing late-stage programs for epcoritamab in follicular lymphoma and chronic lymphocytic leukemia, tisotumab vedotin expansions in solid tumors, and others like acasunlimab and tecaginlimab targeting PD-L1x4-1BB and CD40x4-1BB respectively. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab operates globally through subsidiaries in the Netherlands (Genmab B.V., Utrecht), the United States (Genmab U.S., Inc., Princeton, New Jersey), Japan (Genmab K.K., Tokyo), Germany (Genmab Germany GmbH, Munich) and China (Genmab (Suzhou) Co., Ltd.), with affiliates supporting research, development and commercialization across North America, Europe and Asia Pacific. Recent major developments include the April 2024 acquisition of ProfoundBio for $1.8 billion to expand its antibody-drug conjugate capabilities and oncology portfolio, followed by the September 2025 announcement of an $8.0 billion all-cash acquisition of Merus N.V. (expected to close in early Q1 2026), adding the late-stage petosemtamab (a bispecific antibody with Breakthrough Therapy Designations for head and neck cancer) to accelerate Genmab's shift toward a wholly owned commercial model; these transactions, funded via cash and $5.5 billion in debt financing from Morgan Stanley, enhance late-stage pipeline diversity and project multiple proprietary launches by 2027, alongside 2025 revenue guidance of $3.5-3.7 billion driven by royalty growth from DARZALEX and independent EPKINLY/Tivdak sales expansions in Europe and Japan.

Company News

  • Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT?

  • Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

  • Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

  • Capital Increase in Genmab as a Result of Employee Warrant Exercise

  • Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript

  • What Genmab A/S (GMAB) Said on Its Q3 Earnings Call

  • Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting

  • A little-known biotech's high-stakes cancer bet just paid off and its shares doubled

  • Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript

  • Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches

  • Genmab Stock Hits 52-Week High - Here's Why

  • Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%

  • Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

  • Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

  • Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

  • Genmab's Encouraging Oncology Data Boosts Investor Optimism

  • Genmab Shares Jump After Positive Cancer Study Results

  • Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

  • Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer